Edition:
United Kingdom

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

8,169JPY
20 Jun 2018
Change (% chg)

-- (--)
Prev Close
¥8,169
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,106,287
52-wk High
¥8,388
52-wk Low
¥5,402

Chart for

About

Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company's business segments include pharmaceutical segment and other segment. The pharmaceutical segment is engaged in the research, develop, manufacture and sale of pharmaceuticals for medical use, generic... (more)

Overall

Beta: 0.68
Market Cap(Mil.): ¥1,746,483.00
Shares Outstanding(Mil.): 296.57
Dividend: 80.00
Yield (%): 2.55

Financials

  4523.T Industry Sector
P/E (TTM): 57.32 30.95 32.74
EPS (TTM): 102.73 -- --
ROI: 4.05 14.84 14.38
ROE: 5.24 16.34 16.08

BRIEF-Nichi-Iko Pharmaceutical says business and capital alliance with Eisai

* Says it forms business and capital alliance with Eisai Co Ltd

28 Mar 2018

BRIEF-Anticancer Agent Lenvima Approved For Additional Indication Of Unresectable Hepatocellular Carcinoma In Japan

* ANTICANCER AGENT LENVIMA® (LENVATINIB MESYLATE) APPROVED FOR ADDITIONAL INDICATION OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) IN JAPAN, FIRST APPROVAL WORLDWIDE FOR LENVIMA FOR HCC

23 Mar 2018

Eisai clinches Merck deal to develop and sell cancer drug, shares soar

(This March 8 story has been corrected to show in the 7th paragraph that Merck will pay, not receive, R&D reimbursement)

09 Mar 2018

CORRECTED-UPDATE 3-Eisai clinches Merck deal to develop and sell cancer drug, shares soar

* Eisai's drug Lenvima already approved in dozens of countries

09 Mar 2018

Eisai clinches Merck deal to develop and sell cancer drug, shares soar

NEW YORK/TOKYO Merck & Co Inc and Japan's Eisai Co Ltd have signed a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in dozens of countries for two uses.

08 Mar 2018

BRIEF-Eisai Co, Merck Announce Oncology Collaboration For Lenvima

* EISAI CO., LTD. AND MERCK ENTER GLOBAL STRATEGIC ONCOLOGY COLLABORATION FOR LENVIMA® (LENVATINIB MESYLATE)

07 Mar 2018

Merck, Eisai sign deal to further develop, sell Eisai cancer drug

March 7 Merck & Co and Japan's Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in many countries for two uses.

07 Mar 2018

BRIEF-Morphotek Announces FDA Acceptance Of IND For Cancer Treatment

* MORPHOTEK ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR NEXT-GENERATION FARLETUZUMAB ANTIBODY-DRUG CONJUGATE MORAB-202

10 Jan 2018

BRIEF-Eisai, Merck Receive Breakthrough Therapy Designation From FDA For Lenvima, Keytruda

* EISAI AND MERCK RECEIVE BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR LENVIMA® (LENVATINIB MESYLATE) AND KEYTRUDA® (PEMBROLIZUMAB) AS COMBINATION THERAPY FOR ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA

09 Jan 2018

Earnings vs. Estimates